Editas Medicine said on Thursday it would cut around 180 jobs, representing 65% of its workforce, over the next six months as part of the company's transition towards becoming a developer of therapies ...
Inc. (“Candel”) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological ...
This was the stock's third consecutive day of losses.
LPA’s net-zero energy portfolio includes the Environmental Nature Center Preschool, which earned a COTE Top Ten Plus Award ...
Most sickle cell disease patients who received the gene-editing therapy Casgevy have been free from vaso-occlusive crises for ...
Saudi Arabia’s Ministry of Industry and Mineral Resources signed a memorandum of understanding (MoU) with US-based Vertex ...
Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") reports favorable ongoing efficacy results from the ...
Investing in biotech stocks isn't for everyone because the very nature of their business is fraught with risk. As a result, ...
As reported by the South China Morning Post today, Everest Medicines (HKEX 1952.HK) is accelerating its journey to become a leading biopharmaceutical company in the Asia-Pacific region, driven by ...
In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report). The company’s ...
Though M&A deal value and volume both declined in biopharma in 2024 compared to the year prior, PwC analysts still believe ...
South Africa's Competition Commission initiated an investigation into Vertex Pharmaceuticals for alleged excessive pricing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback